Therapeutic Targeting the Allosteric Cysteinome of RAS and Kinase Families

The protein kinase complement of the human genome

Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145 · see citing works

Lipid rafts and signal transduction

Simons, K., & Toomre, D. K. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036052 · Cited by 6,252 · see citing works

Signal transduction by receptors with tyrosine kinase activity

Ullrich, A., & Schlessinger, J. (1990) · Cell · doi:10.1016/0092-8674(90)90801-k · Cited by 5,435 · see citing works

DrugBank: a comprehensive resource for in silico drug discovery and exploration

Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892 · see citing works

Oncogenic kinase signalling.

Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738 · see citing works

Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain

Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · see citing works

Improved protein structure prediction using potentials from deep learning

Senior, A. W., Evans, R., Jumper, J., Kirkpatrick, J., Sifre, L., Green, T., Qin, C., Žídek, A., Nelson, A. W. R., Bridgland, A., et al. (2020) · Nature · doi:10.1038/s41586-019-1923-7 · Cited by 3,378 · see citing works

Defining a Cancer Dependency Map

Tsherniak, A., Vazquez, F., Montgomery, P. G., Weir, B. A., Kryukov, G., Cowley, G. S., Gill, S., Harrington, W. F., Pantel, S., Krill-Burger, J. M., et al. (2017) · Cell · doi:10.1016/j.cell.2017.06.010 · Cited by 3,276 · see citing works

Stereochemistry of Cooperative Effects in Haemoglobin: Haem–Haem Interaction and the Problem of Allostery

Perutz, M. F. (1970) · Nature · doi:10.1038/228726a0 · Cited by 2,931 · see citing works

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557 · see citing works

The Clinical KRAS(G12C) Inhibitor AMG 510 Drives Anti-Tumour Immunity

Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., Gaida, K., Holt, T., Knutson, C. G., Koppada, N., et al. (2019) · Nature · doi:10.1038/s41586-019-1694-1 · Cited by 2,277 · see citing works

A Comprehensive Survey of Ras Mutations in Cancer

Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works

Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells

Meyers, R. M., Bryan, J. G., McFarland, J. M., Weir, B. A., Sizemore, A. E., Xu, H., Dharia, N. V., Montgomery, P. G., Cowley, G. S., Pantel, S., et al. (2017) · Nature Genetics · doi:10.1038/ng.3984 · Cited by 1,952 · see citing works

Mammalian Rho GTPases: new insights into their functions from in vivo studies

Heasman, S. J., & Ridley, A. J. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2476 · Cited by 1,871 · see citing works

The Conformational Plasticity of Protein Kinases

Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,760 · see citing works

KRAS ^G12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., Falchook, G. S., Price, T. J., Sacher, A., Denlinger, C. S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917239 · Cited by 1,733 · see citing works

The Ras-RasGAP Complex: Structural Basis for GTPase Activation and Its Loss in Oncogenic Ras Mutants

Scheffzek, K., Ahmadian, M. R., Kabsch, W., Wiesmüller, L., Lautwein, A., Schmitz, F., & Wittinghofer, A. (1997) · Science · doi:10.1126/science.277.5324.333 · Cited by 1,543 · see citing works

The ensemble nature of allostery

Motlagh, H. N., Wrabl, J. O., Li, J., & Hilser, V. J. (2014) · Nature · doi:10.1038/nature13001 · Cited by 1,247 · see citing works

Protein Tyrosine Kinase Structure and Function

Hubbard, S. R., & Till, J. H. (2000) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.69.1.373 · Cited by 1,176 · see citing works

Targeting KRAS mutant cancers with a covalent G12C-specific inhibitor

Janes, M. R., Zhang, J., Li, L.-S., Hansen, R., Peters, U., Guo, X., Chen, Y., Babbar, A., Firdaus, S. J., Darjania, L., et al. (2018) · Cell · doi:10.1016/j.cell.2018.01.006 · Cited by 1,172 · see citing works

RAS-targeted therapies: is the undruggable drugged?

Moore, A. R., Rosenberg, S. C., McCormick, F., & Malek, S. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0068-6 · Cited by 1,103 · see citing works

Rational design and characterization of a Rac GTPase-specific small molecule inhibitor

Gao, Y., Dickerson, J. B., Guo, F., Zheng, J., & Zheng, Y. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307512101 · Cited by 1,091 · see citing works

General Conclusions: Teleonomic Mechanisms in Cellular Metabolism, Growth, and DifferentiationPreprint

Monod, J., & Jacob, F. (1961) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.1961.026.01.048 · Cited by 1,072 · see citing works

Molecular Switch for Signal Transduction: Structural Differences Between Active and Inactive Forms of Protooncogenic ras Proteins

Milburn, M. V., Tong, L., deVos, A. M., Brünger, A. T., Yamaizumi, Z., Nishimura, S., & Kim, S. (1990) · Science · doi:10.1126/science.2406906 · Cited by 1,062 · see citing works

Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors

Jia, Y., Yun, C., Park, E., Ercan, D., Manuia, M., Juarez, J., Xu, C., Rhee, K., Chen, T., Zhang, H., et al. (2016) · Nature · doi:10.1038/nature17960 · Cited by 933 · see citing works

ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

Wakeling, A. E., Guy, S. P., Woodburn, J. R., Ashton, S. E., Curry, B. J., Barker, A. J., & Gibson, K. H. (2002) · PubMed · doi:10.7270/q2pc374f · Cited by 925 · see citing works

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases

Chen, Y.-N. P., LaMarche, M. J., Chan, H. M., Fekkes, P., Garcia-Fortanet, J., Acker, M. G., Antonakos, B., Chen, C. H.-T., Chen, Z., Cooke, V. G., et al. (2016) · Nature · doi:10.1038/nature18621 · Cited by 925 · see citing works

K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors

Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884 · see citing works

Is allostery an intrinsic property of all dynamic proteins?

Gunasekaran, K., Ma, B., & Nussinov, R. (2004) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.20232 · Cited by 882 · see citing works

Trends in kinase drug discovery: targets, indications and inhibitor design

Attwood, M. M., Fabbro, D., Sokolov, A. V., Knapp, S., & Schiöth, H. B. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00252-y · Cited by 807 · see citing works

Dragging ras back in the ring

Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

Hunter, J. C., Manandhar, A., Carrasco, M. A., Gurbani, D., Gondi, S., & Westover, K. D. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0203 · Cited by 786 · see citing works

Allostery in Disease and in Drug Discovery

Nussinov, R., & Tsai, C. (2013) · Cell · doi:10.1016/j.cell.2013.03.034 · Cited by 764 · see citing works

Selective inhibition of oncogenic KRAS output with small molecules targeting the inactive state

Patricelli, M. P., Janes, M. R., Li, L.-S., Hansen, R., Peters, U., Kessler, L. V., Chen, Y., Kucharski, J. M., Feng, J., Ely, T., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1105 · Cited by 759 · see citing works

The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes

Ellis, R. W., DeFeo, D., Shih, T. Y., Gonda, M. A., Young, H. A., Tsuchida, N., Lowy, D. R., & Scolnick, E. M. (1981) · Nature · doi:10.1038/292506a0 · Cited by 723 · see citing works

Allele-specific inhibitors inactivate mutant KRAS G12C by a trapping mechanism

Lito, P., Solomon, M., Li, L.-S., Hansen, R., & Rosen, N. (2016) · Science · doi:10.1126/science.aad6204 · Cited by 691 · see citing works

NRAS mutation status is an independent prognostic factor in metastatic melanoma

Jakob, J. A., Bassett, R. L., Ng, C. S., Curry, J. L., Joseph, R. W., Alvarado, G. C., Rohlfs, M. L., Richard, J., Gershenwald, J. E., Kim, K. B., et al. (2011) · Cancer · doi:10.1002/cncr.26724 · Cited by 690 · see citing works

Developing Irreversible Inhibitors of the Protein Kinase Cysteinome

Liu, Q., Sabnis, Y. A., Zhao, Z., Zhang, T., Buhrlage, S. J., Jones, L. H., & Gray, N. S. (2013) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.12.006 · Cited by 662 · see citing works

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition

Ohren, J. F., Chen, H., Pavlovsky, A. G., Whitehead, C. E., Zhang, E., Kuffa, P., Yan, C., McConnell, P., Spessard, C., Banotai, C. A., et al. (2004) · Nature Structural & Molecular Biology · doi:10.1038/nsmb859 · Cited by 635 · see citing works

The 2.2 Å crystal structure of the Ras-binding domain of the serine/threonine kinase c-Raf1 in complex with RaplA and a GTP analogue

Nassar, N. N., Horn, G., Herrmann, C., Scherer, A., McCormick, F. P., & Wittinghofer, A. (1995) · Nature · doi:10.1038/375554a0 · Cited by 631 · see citing works

The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Wylie, A. A., Schoepfer, J. G., Jahnke, W., Cowan‐Jacob, S. W., Loo, A. T., Furet, P., Marzinzik, A. L., Pellé, X., Donovan, J., Zhu, W. S., et al. (2017) · Nature · doi:10.1038/nature21702 · Cited by 622 · see citing works

The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

Deininger, M. W., Goldman, J. M., Lydon, N., & Melo, J. V. (1997) · Blood · doi:10.1182/blood.v90.9.3691 · Cited by 618 · see citing works

Targeting Bcr–Abl by combining allosteric with ATP-binding-site inhibitors

Zhang, J., Adrián, F., Jahnke, W., Cowan‐Jacob, S. W., Li, A. G., Iacob, R. E., Sim, T., Powers, J. T., Dierks, C., Sun, F., et al. (2010) · Nature · doi:10.1038/nature08675 · Cited by 603 · see citing works

An Unidentified Virus which causes the Rapid Production of Tumours in Mice

Harvey, J. J. (1964) · Nature · doi:10.1038/2041104b0 · Cited by 554 · see citing works

Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

Ramalingam, S. S., Yang, J. C., Lee, C. K., Kurata, T., Kim, D., John, T., Nogami, N., Ohe, Y., Mann, H., Rukazenkov, Y., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7576 · Cited by 554 · see citing works

Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.

Infante, J. R., Fecher, L. A., Falchook, G. S., Nallapareddy, S., Gordon, M. S., Becerra, C., DeMarini, D. J., Cox, D. S., Xu, Y., Morris, S. R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70270-x · Cited by 552 · see citing works

Molecular characterization of CDC42, a Saccharomyces cerevisiae gene involved in the development of cell polarity.

Johnson, D. I., & Pringle, J. R. (1990) · The Journal of Cell Biology · doi:10.1083/jcb.111.1.143 · Cited by 543 · see citing works

Rho GTPases

Mackay, D., & Hall, A. K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.33.20685 · Cited by 540 · see citing works

Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy

Grimsby, J. S., Sarabu, R., Corbett, W. L., Haynes, N.-E., Bizzarro, F. T., Coffey, J. W., Guertin, K. R., Hilliard, D. W., Kester, R. F., Mahaney, P. E., et al. (2003) · Science · doi:10.1126/science.1084073 · Cited by 526 · see citing works

Structural Basis for Allosteric Regulation of the Monomeric Allosteric Enzyme Human Glucokinase

Kamata, K., Mitsuya, M., Nishimura, T., Eiki, J., & Nagata, Y. (2004) · Structure · doi:10.1016/j.str.2004.02.005 · Cited by 502 · see citing works

Discovery of Small Molecules that Bind to K‐Ras and Inhibit Sos‐Mediated Activation

Sun, Q., Burke, J. P., Phan, J., Burns, M. C., Olejniczak, E. T., Waterson, A. G., Lee, T., Rossanese, O. W., & Fesik, S. W. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201201358 · Cited by 490 · see citing works

A Myristoyl/Phosphotyrosine Switch Regulates c-Abl

Hantschel, O. D., Nagar, B., Guettler, S., Kretzschmar, J., Dorey, K., Kuriyan, J., & Superti‐Furga, G. (2003) · Cell · doi:10.1016/s0092-8674(03)00191-0 · Cited by 482 · see citing works

Drugging an undruggable pocket on KRAS

Kessler, D., Gmachl, M., Mantoulidis, A., Martin, L. J., Zoephel, A., Mayer, M., Gollner, A., Covini, D., Fischer, S., Gerstberger, T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1904529116 · Cited by 449 · see citing works

Harvey murine sarcoma virus p21 ras protein: biological and biochemical significance of the cysteine nearest the carboxy terminus.

Willumsen, B. M., Norris, K. E., Papageorge, A. G., Hubbert, N. L., & Lowy, D. R. (1984) · The EMBO Journal · doi:10.1002/j.1460-2075.1984.tb02177.x · Cited by 399 · see citing works

Targeting FAK in anticancer combination therapies

Dawson, J. C., Serrels, A., Stupack, D. G., Schlaepfer, D. D., & Frame, M. C. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00340-6 · Cited by 397 · see citing works

Covalent inhibitors: a rational approach to drug discovery

Sutanto, F., Konstantinidou, M., & Dömling, A. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00154f · Cited by 389 · see citing works

The Evolution of Protein Kinase Inhibitors from Antagonists to Agonists of Cellular Signaling

Dar, A. C., & Shokat, K. M. (2011) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-090308-173656 · Cited by 388 · see citing works

Allosteric inhibitors of Bcr-abl–dependent cell proliferation

Adrián, F., Ding, Q., Sim, T., Velentza, A. V., Sloan, C., Liu, Y., Zhang, G., Hur, W., Ding, S., Manley, P. W., et al. (2006) · Nature Chemical Biology · doi:10.1038/nchembio760 · Cited by 381 · see citing works

Three-dimensional structures of H-ras p21 mutants: molecular basis for their inability to function as signal switch molecules.

Krengel, U., Schlichting, I., Scherer, A., Schumann, R., Frech, M., John, J., Kabsch, W., Pai, E., & Wittinghofer, A. (1994) · Cell · doi:10.1016/0092-8674(90)90018-a · Cited by 374 · see citing works

Ten things you should know about protein kinases: IUPHAR R eview 14

Fabbro, D., Cowan‐Jacob, S. W., & Möbitz, H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13096 · Cited by 350 · see citing works

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)

Blumenschein, G. R., Smit, E. F., Planchard, D., Kim, D.-W., Cadranel, J., De Pas, T., Dunphy, F., Udud, K., Ahn, M.-J., Hanna, N. H., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv072 · Cited by 349 · see citing works

GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

Loomba, R., Kayali, Z., Noureddin, M., Ruane, P., Lawitz, E. J., Bennett, M., Wang, L., Harting, E., Tarrant, J. M., McColgan, B. J., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.07.027 · Cited by 340 · see citing works

FDA Approval Summary: Sotorasib for <i>KRAS G12C</i> -Mutated Metastatic NSCLC

Nakajima, E. C., Drezner, N., Li, X., Mishra-Kalyani, P. S., Liu, Y., Zhao, H., Bi, Y., Liu, J., Rahman, A., Wearne, E., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3074 · Cited by 333 · see citing works

Advances in covalent kinase inhibitors

Abdeldayem, A., Raouf, Y. S., Constantinescu, S. N., Moriggl, R., & Gunning, P. T. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00720b · Cited by 332 · see citing works

Rho GTPase function in tumorigenesis

Karlsson, R. T. G., Pedersen, E., Wang, Z., & Brakebusch, C. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.003 · Cited by 331 · see citing works

Morphologic Responses to a Murine Erythroblastosis Virus 2

KIRSTEN, W. H., & Mayer, L. A. (1967) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/39.2.311 · Cited by 306 · see citing works

Identification of a pocket in the PDK1 kinase domain that interacts with PIF and the C‐terminal residues of PKA

Biondi, R. M., Cheung, P., Casamayor, A., Deák, M., Currie, R. A., & Alessi, D. R. (2000) · The EMBO Journal · doi:10.1093/emboj/19.5.979 · Cited by 301 · see citing works

Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor

Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300 · see citing works

Allosteric inhibition of SHP2: identification of a potent, selective, and orally efficacious phosphatase inhibitor

Garcia Fortanet, J., Chen, C. H.-T., Chen, Y.-N. P., Chen, Z., Deng, Z., Firestone, B., Fekkes, P., Fodor, M., Fortin, P. D., Fridrich, C., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00680 · Cited by 298 · see citing works

The Central Role of Glucokinase in Glucose Homeostasis: A Perspective 50 Years After Demonstrating the Presence of the Enzyme in Islets of Langerhans

Matschinsky, F. M., & Wilson, D. F. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00148 · Cited by 296 · see citing works

KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS

Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270 · see citing works

RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis

Bid, H. K., Roberts, R. D., Manchanda, P. K., & Houghton, P. J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0164 · Cited by 265 · see citing works

Covalent Inhibition in Drug Discovery

Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265 · see citing works

Lysine‐Targeting Covalent Inhibitors

Pettinger, J., Jones, K., & Cheeseman, M. D. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707630 · Cited by 244 · see citing works

In situ selectivity profiling and crystal structure of SML-8-73-1, an active site inhibitor of oncogenic K-Ras G12C

Hunter, J. C., Gurbani, D., Ficarro, S. B., Carrasco, M. A., Lim, S. M., Choi, H. G., Xie, T., Marto, J. A., Chen, Z., Gray, N. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1404639111 · Cited by 242 · see citing works

Characterization of EHop-016, Novel Small Molecule Inhibitor of Rac GTPase

Montalvo-Ortiz, B. L., Castillo‐Pichardo, L., O'Farril, E. H., Humphries‐Bickley, T., Mota‐Peynado, A. D. L., Cubano, L. A., Vlaar, C. P., & Dharmawardhane, S. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334524 · Cited by 240 · see citing works

Structural basis for regulation of human acetyl-CoA carboxylase

Hunkeler, M., Hagmann, A., Stuttfeld, E., Chami, M., Guri, Y., Stahlberg, H., & Maier, T. (2018) · Nature · doi:10.1038/s41586-018-0201-4 · Cited by 229 · see citing works

Rational Design of Small Molecule Inhibitors Targeting RhoA Subfamily Rho GTPases

Shang, X., Marchioni, F., Sipes, N. S., Evelyn, C. R., Jerabek‐Willemsen, M., Duhr, S., Seibel, W. L., Wortman, M. D., & Zheng, Y. (2012) · Chemistry & Biology · doi:10.1016/j.chembiol.2012.05.009 · Cited by 226 · see citing works

Properties of FDA-approved small molecule protein kinase inhibitors: A 2022 update

Roskoski, R. J. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106037 · Cited by 208 · see citing works

Tissue-Specific Oncogenic Activity of KRASA146T

Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197 · see citing works

New Directions in Targeting Protein Kinases: Focusing Upon True Allosteric and Bivalent Inhibitors

Lamba, V., & Ghosh, I. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212800672813 · Cited by 182 · see citing works

New Look at Hemoglobin Allostery

Yuan, Y., Tam, M. F., Simplăceanu, V., & Ho, C. (2015) · Chemical Reviews · doi:10.1021/cr500495x · Cited by 176 · see citing works

Small molecule targeting Cdc42–intersectin interaction disrupts Golgi organization and suppresses cell motility

Friesland, A., Zhao, Y., Chen, Y., Wang, L., Zhou, H., & Lu, Q. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1116051110 · Cited by 175 · see citing works

New Promise and Opportunities for Allosteric Kinase Inhibitors

Lu, X., Smaill, J. B., & Ding, K. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201914525 · Cited by 170 · see citing works

Characterization of a Cdc42 Protein Inhibitor and Its Use as a Molecular Probe

Lin, H., Kenney, S. R., Phillips, G. K., Simpson, D. S., Schroeder, C. E., Nöth, J., Romero, E., Swanson, S., Waller, A., Strouse, J. J., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.435941 · Cited by 169 · see citing works

Allosteric Methods and Their Applications: Facilitating the Discovery of Allosteric Drugs and the Investigation of Allosteric Mechanisms

Lu, S., Shen, Q., & Zhang, J. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.8b00570 · Cited by 166 · see citing works

Structures of human phosphofructokinase-1 and atomic basis of cancer-associated mutations

Webb, B. A., Forouhar, F., Szu, F.-E., Seetharaman, J., Tong, L., & Barber, D. L. (2015) · Nature · doi:10.1038/nature14405 · Cited by 163 · see citing works

Secramine inhibits Cdc42-dependent functions in cells and Cdc42 activation in vitro

Pelish, H. E., Peterson, J. R., Salvarezza, S. B., Rodriguez-Boulan, E. J., Chen, J., Stamnes, M. A., Macia, E., Feng, Y., Shair, M. D., & Kirchhausen, T. L. (2005) · Nature Chemical Biology · doi:10.1038/nchembio751 · Cited by 162 · see citing works

Turning a protein kinase on or off from a single allosteric site via disulfide trapping

Sadowsky, J., Burlingame, M. A., Wolan, D. W., McClendon, C. L., Jacobson, M. P., & Wells, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102376108 · Cited by 155 · see citing works

The reactivity-driven biochemical mechanism of covalent KRASG12C inhibitors

Hansen, R., Peters, U., Babbar, A., Chen, Y., Feng, J., Janes, M. R., Li, L.-S., Ren, P., Liu, Y., & Zarrinkar, P. P. (2018) · Nature Structural &amp; Molecular Biology · doi:10.1038/s41594-018-0061-5 · Cited by 153 · see citing works

Acetyl-CoA carboxylase (ACC) as a therapeutic target for metabolic syndrome and recent developments in ACC1/2 inhibitors

Chen, L., Duan, Y., Wei, H., Ning, H., Bi, C., Zhao, Y., Qin, Y. W., & Li, Y. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1657825 · Cited by 147 · see citing works

Potent and Selective Covalent Quinazoline Inhibitors of KRAS G12C

Zeng, M., Lu, J., Li, L., Feru, F., Quan, C., Gero, T. W., Ficarro, S. B., Xiong, Y., Ambrogio, C., Paranal, R. M., et al. (2017) · Cell Chemical Biology · doi:10.1016/j.chembiol.2017.06.017 · Cited by 136 · see citing works

Regulation of mammalian muscle type 6‐phosphofructo‐1‐kinase and its implication for the control of the metabolism

Sola‐Penna, M., Da Silva, D., Coelho, W. S., Marinho‐Carvalho, M. M., & Zancan, P. (2010) · IUBMB Life · doi:10.1002/iub.393 · Cited by 135 · see citing works

Dual Allosteric Inhibition of SHP2 Phosphatase

Fodor, M., Price, E. V., Wang, P., Lu, H., Argintaru, A., Chen, Z., Glick, M., Hao, H.-X., Kato, M., Koenig, R., et al. (2018) · ACS Chemical Biology · doi:10.1021/acschembio.7b00980 · Cited by 133 · see citing works

A new screening assay for allosteric inhibitors of cSrc

Simard, J. R., Klüter, S., Grütter, C., Getlik, M., Rabiller, M., Rode, H. B., & Rauh, D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.162 · Cited by 129 · see citing works

10 Years Into the Resurgence of Covalent Drugs

Vita, E. D. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2020-0236 · Cited by 125 · see citing works

Ras oncoprotein inhibitors: The discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex

Taveras, A. G., Remiszewski, S., Doll, R. J., Cesarz, D., Huang, E. C., Kirschmeier, P. T., Pramanik, B. N., Snow, M. E., Wang, Y.-S., del Rosario, J., et al. (1997) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(96)00202-7 · Cited by 123 · see citing works

KRAS is vulnerable to reversible switch-II pocket engagement in cells

Vasta, J. D., Peacock, D. M., Zheng, Q., Walker, J. A., Zhang, Z., Zimprich, C. A., Thomas, M. R., Beck, M. T., Binkowski, B. F., Corona, C. R., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-00985-w · Cited by 115 · see citing works

Optimization of a Dibenzodiazepine Hit to a Potent and Selective Allosteric PAK1 Inhibitor

Karpov, A. S., Amiri, P., Bellamacina, C. R., Bellance, M.-H., Breitenstein, W., Daniel, D., Denay, R., Fabbro, D., Fernández, C. F., Galuba, I., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00102 · Cited by 113 · see citing works

Discovery and Optimization of a Series of 3-(3-Phenyl-3 H -imidazo[4,5- b ]pyridin-2-yl)pyridin-2-amines: Orally Bioavailable, Selective, and Potent ATP-Independent Akt Inhibitors

Ashwell, M. A., Lapierre, J., Brassard, C. J., Bresciano, K. R., Bull, C. O., Cornell-Kennon, S., Eathiraj, S., France, D. S., Hall, T. G., Hill, J. E., et al. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300276x · Cited by 113 · see citing works

Disrupting the Scaffold to Improve Focal Adhesion Kinase–Targeted Cancer Therapeutics

Cance, W. G., Kurenova, E., Marlowe, T. A., & Golubovskaya, V. (2013) · Science Signaling · doi:10.1126/scisignal.2004021 · Cited by 98 · see citing works

Affinity Profiling of the Cellular Kinome for the Nucleotide Cofactors ATP, ADP, and GTP

Becher, I., Savitski, M. M., Savitski, M. F., Hopf, C., Bantscheff, M., & Drewes, G. (2012) · ACS Chemical Biology · doi:10.1021/cb3005879 · Cited by 96 · see citing works

Electrophilic warheads in covalent drug discovery: an overview

Péczka, N., Orgován, Z., Ábrányi‐Balogh, P., & Keserű, G. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2034783 · Cited by 92 · see citing works

A small-molecule mimic of a peptide docking motif inhibits the protein kinase PDK1

Rettenmaier, T. J., Sadowsky, J., Thomsen, N. D., Chen, S. C., Doak, A. K., Arkin, M. R., & Wells, J. A. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1415365112 · Cited by 91 · see citing works

Acetyl-CoA carboxylase-a as a novel target for cancer therapy

Cao, D. (2009) · Frontiers in Bioscience-Scholar · doi:10.2741/s82 · Cited by 90 · see citing works

Targeting Cdc42 in cancer

Arias‐Romero, L. E., & Chernoff, J. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.828037 · Cited by 79 · see citing works

Discovery and Characterization of Non-ATP Site Inhibitors of the Mitogen Activated Protein (MAP) Kinases

Comess, K. M., Sun, C. C., Abad‐Zapatero, C., Goedken, E. R., Gum, R. J., Borhani, D. W., Argiriadi, M. A., Groebe, D. R., Jia, Y., Clampit, J. E., et al. (2010) · ACS Chemical Biology · doi:10.1021/cb1002619 · Cited by 79 · see citing works

99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation

Riely, G. J., Ou, S.-H. I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J. K., Johnson, M., Heist, R. S., Bazhenova, L., Barve, M., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(21)01941-9 · Cited by 77 · see citing works

Development of thioquinazolinones, allosteric Chk1 kinase inhibitors

Converso, A., Hartingh, T. J., Garbaccio, R. M., Tasber, E. S., Rickert, K. W., Fraley, M. E., Yan, Y., Kreatsoulas, C., Stirdivant, S. M., Drakas, B. A., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.076 · Cited by 75 · see citing works

Allosteric Interactions between the Myristate- and ATP-Site of the Abl Kinase

Iacob, R. E., Zhang, J., Gray, N. S., & Engen, J. R. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015929 · Cited by 73 · see citing works

Discovery of a Type III Inhibitor of LIM Kinase 2 That Binds in a DFG-Out Conformation

Goodwin, N. C., Cianchetta, G., Burgoon, H. A., Healy, J. P., Mabon, R., Strobel, E. D., Allen, J., Wang, S., Hamman, B. D., & Rawlins, D. B. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml500242y · Cited by 70 · see citing works

Affinity of guanine nucleotide binding proteins for their ligands: facts and artefacts

Goody, R. S., Frech, M., & Wittinghofer, A. (1991) · Trends in Biochemical Sciences · doi:10.1016/0968-0004(91)90134-h · Cited by 69 · see citing works

A structural model of a Ras–Raf signalosome

Mysore, V. P., Zhou, Z.-W., Ambrogio, C., Li, L., Kapp, J. N., Lu, C., Wang, Q., Tucker, M. R., Okoro, J. J., Nagy‐Davidescu, G., et al. (2021) · Nature Structural & Molecular Biology · doi:10.1038/s41594-021-00667-6 · Cited by 69 · see citing works

Along the allostery stream: Recent advances in computational methods for allosteric drug discovery

Ni, D., Chai, Z., Wang, Y., Li, M., Yu, Z., Liu, Y., Lu, S., & Zhang, J. (2021) · Wiley Interdisciplinary Reviews Computational Molecular Science · doi:10.1002/wcms.1585 · Cited by 67 · see citing works

Covalent Guanosine Mimetic Inhibitors of G12C KRAS

Xiong, Y., Lu, J., Hunter, J., Li, L., Scott, D., Choi, H. G., Lim, S. M., Manandhar, A., Gondi, S., Sim, T., et al. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00373 · Cited by 66 · see citing works

The small molecule BI-2852 induces a nonfunctional dimer of KRAS

Tran, T. H., Alexander, P., Dharmaiah, S., Agamasu, C., Nissley, D. V., McCormick, F., Esposito, D., Simanshu, D. K., Stephen, A. G., & Balius, T. E. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1918164117 · Cited by 65 · see citing works

Dorzagliatin (HMS5552), a novel dual‐acting glucokinase activator, improves glycaemic control and pancreatic β‐cell function in patients with type 2 diabetes: A 28‐day treatment study using biomarker‐guided patient selection

Zhu, X., Zhu, D., Li, X., Li, Y., Jin, X., Hu, T., Zhao, Y., Li, Y., Zhao, G., Ren, S., et al. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13338 · Cited by 62 · see citing works

Structure-based discovery of cellular-active allosteric inhibitors of FAK

Tomita, N., Hayashi, Y., Suzuki, S., Oomori, Y., Aramaki, Y., Matsushita, Y., Iwatani, M., Iwata, H., Okabe, A., Awazu, Y., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.047 · Cited by 57 · see citing works

Discovery of Allosteric, Potent, Subtype Selective, and Peripherally Restricted TrkA Kinase Inhibitors

Bagal, S. K., Omoto, K., Blakemore, D. C., Bungay, P. J., Bilsland, J., Clarke, P. J., Corbett, M. S., Cronin, C. N., Cui, J. J., Dias, R., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00280 · Cited by 57 · see citing works

Expression, purification, and characterization of human and rat acetyl cfenzyme A carboxylase (ACC) isozymes

Cheng, D., Chu, C.-H., Chen, L., Feder, J. N., Mintier, G. A., Wu, Y., Cook, J. W., Harpel, M. R., Locke, G. A., An, Y., et al. (2006) · Protein Expression and Purification · doi:10.1016/j.pep.2006.06.005 · Cited by 53 · see citing works

KRAS Switch Mutants D33E and A59G Crystallize in the State 1 Conformation

Lu, J., Bera, A. K., Gondi, S. R., & Westover, K. D. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00974 · Cited by 50 · see citing works

The Tousled-like kinases regulate genome and epigenome stability: implications in development and disease

Segura‐Bayona, S., & Stracker, T. H. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03208-z · Cited by 50 · see citing works

Interaction of a Novel GDP Exchange Inhibitor with the Ras Protein

Ganguly, A. K., Wang, Y., Pramanik, B. N., Doll, R. J., Snow, M. E., Taveras, A. G., Remiszewski, S., Cesarz, D., del Rosario, J., Vibulbhan, B., et al. (1998) · Biochemistry · doi:10.1021/bi9805691 · Cited by 49 · see citing works

Allosteric IGF-1R Inhibitors

Heinrich, T., Grädler, U., Böttcher, H., Blaukat, A., & Shutes, A. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml100044h · Cited by 49 · see citing works

Insights into the binding mode of MEK type-III inhibitors. A step towards discovering and designing allosteric kinase inhibitors across the human kinome

Zhao, Z., Xie, L., & Bourne, P. E. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179936 · Cited by 48 · see citing works

Molecular basis of Tousled-Like Kinase 2 activation

Mortuza, G. B., Hermida, D., Pedersen, A.-K., Segura‐Bayona, S., Mendez, B. L., Redondo, P. N., Rüther, P. L., Pozdnyakova, I., Garrote, A. M., Muñoz, I. G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04941-y · Cited by 45 · see citing works

Fast acting allosteric phosphofructokinase inhibitors block trypanosome glycolysis and cure acute African trypanosomiasis in mice

McNae, I. W., Kinkead, J., Malik, D., Yen, L.-H., Walker, M. K., Swain, C., Webster, S. P., Gray, N., Fernandes, P. M., Myburgh, E., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21273-6 · Cited by 39 · see citing works

Crystal structure of human platelet phosphofructokinase-1 locked in an activated conformation

Kloos, M., Brüser, A., Kirchberger, J., Schöneberg, T., & Sträter, N. (2015) · Biochemical Journal · doi:10.1042/bj20150251 · Cited by 35 · see citing works

A resource for exploring the understudied human kinome for research and therapeutic opportunitiesPreprint

Moret, N., Liu, C., Gyori, B. M., Bachman, J. A., Steppi, A., Hug, C. B., Taujale, R., Huang, L., Berginski, M. E., Gomez, S. M., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.02.022277 · Cited by 32 · see citing works

Detection and structural characterization of ras oncoprotein-inhibitors complexes by electrospray mass spectrometry

Ganguly, A. K., Pramanik, B. N., Huang, E. C., Liberles, S., Heimark, L., Liu, Y. H., Tsarbopoulos, A., Doll, R. J., Taveras, A. G., Remiszewski, S., et al. (1997) · Bioorganic &amp; Medicinal Chemistry · doi:10.1016/s0968-0896(97)00021-7 · Cited by 31 · see citing works

Structural basis of the atypical activation mechanism of KRASV14I

Bera, A. K., Lu, J., Wales, T. E., Gondi, S. R., Gurbani, D., Nelson, A., Engen, J. R., & Westover, K. D. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.009131 · Cited by 30 · see citing works

Displacement Assay for the Detection of Stabilizers of Inactive Kinase Conformations

Klüter, S., Grütter, C., Naqvi, T., Rabiller, M., Simard, J. R., Pawar, V. T., Getlik, M., & Rauh, D. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901297e · Cited by 28 · see citing works

New Insights in Protein Kinase Conformational Dynamics

Saladino, G., & Gervasio, F. L. (2012) · Current Topics in Medicinal Chemistry · doi:10.2174/156802612804547407 · Cited by 26 · see citing works

Protein Allostery in Drug Discovery

(2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-8719-7 · Cited by 25 · see citing works

Allostery in Drug Development

Cheng, X., & Jiang, H. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-8719-7_1 · Cited by 23 · see citing works

Design, synthesis and biological evaluation of novel glucokinase activators

Li, Y. Q., Zhang, Y. L., Hu, S. Q., Wang, Y. L., Song, H. R., Feng, Z. Q., Lei, L., Liu, Q., & Shen, Z. F. (2010) · Chinese Chemical Letters · doi:10.1016/j.cclet.2010.07.023 · Cited by 16 · see citing works

Safety, tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator PB-201 and its effects on the glucose excursion profile in drug-naïve Chinese patients with type 2 diabetes: a randomised controlled, crossover, single-centre phase 1 trial

Liu, D., Du, Y., Yao, X., Wei, Y., Zhu, J., Cui, C., Zhou, H., Xu, M., Li, H., & Ji, L. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101185 · Cited by 11 · see citing works

GTP hydrolysis is modulated by Arg34 in the RASopathy‐associated KRASP34R

Bera, A. K., Lu, J., Lu, C., Li, L., Gondi, S. R., Yan, W., Nelson, A., Zhang, G., & Westover, K. D. (2020) · Birth Defects Research · doi:10.1002/bdr2.1647 · Cited by 8 · see citing works

Structural dataset for the fast-exchanging KRAS G13D

Lu, J., Hunter, J., Manandhar, A., Gurbani, D., & Westover, K. D. (2015) · Data in Brief · doi:10.1016/j.dib.2015.10.001 · Cited by 6 · see citing works

First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation

(2019) · Case Medical Research · doi:10.31525/ct1-nct04006301 · Cited by 6 · see citing works

A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation

(2019) · Case Medical Research · doi:10.31525/ct1-nct04165031 · Cited by 3 · see citing works

AlphaFold, Artificial Intelligence (AI), and Allostery

Nussinov, R., Zhang, M., Liu, Y., & Jang, H. (2022) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c04346 · Cited by 190 · see citing works

Multiscale Allostery: Basic Mechanisms and Versatility in Diagnostics and Drug Design

Berezovsky, I. N., & Nussinov, R. (2022) · Journal of Molecular Biology · doi:10.1016/j.jmb.2022.167751 · Cited by 36 · see citing works

Molecular dynamics simulations for the structure-based drug design: targeting small-GTPases proteins

Parise, A., Cresca, S., & Magistrato, A. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2387856 · Cited by 27 · see citing works

Computer-Aided Drug Design Boosts RAS Inhibitor Discovery

Wang, G., Bai, Y., Cui, J., Zong, Z., Gao, Y., & Zheng, Z. (2022) · Molecules · doi:10.3390/molecules27175710 · Cited by 27 · see citing works

Covalent binding of withanolides to cysteines of protein targets

Bailly, C. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116405 · Cited by 15 · see citing works

An in-depth review of AI-powered advancements in cancer drug discovery

Le, M. H. N., Nguyen, P. K., Nguyen, T. P. T., Nguyen, H. Q., Tam, D. N. H., Huynh, H. H., Huynh, P. K., & Le, N. Q. K. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.167680 · Cited by 15 · see citing works

AlphaFold for a medicinal chemist: tool or toy?

Ivanenkov, Y. A., Evteev, S. A., Малышев, А. В., Terentiev, V. A., Bezrukov, D. S., Ereshchenko, A., Korzhenevskaya, A. A., Zagribelnyy, B. A., Шегай, П. В., & Каприн, А. Д. (2024) · Russian Chemical Reviews · doi:10.59761/rcr5107 · Cited by 3 · see citing works

Redox, cysteines, and kinases—A triad sustaining myeloid leukemia

Marensi, V. (2024) · Advances in cancer research · doi:10.1016/bs.acr.2024.04.008 · Cited by 3 · see citing works

Artificial intelligence-based protein structure prediction and systems biology-guided smart drug screening

Chandra, A., Goyal, N., Behera, A., Samanta, J., & Sharma, T. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-16013-4.00016-6 · Cited by 3 · see citing works

The Construction of a Molecular Model for the Ternary Protein Complex of Intrinsic Coagulation Pathway Factors Provides Novel Insights for the Pathogenesis of Cross-Reactive Material Positive Coagulation Factor Mutations

Jiang, S., Li, F., Li, L., Wang, X., Wei, D., Wu, W., & Xu, Q. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115191 · Cited by 2 · see citing works

Harnessing AI to decode protein kinases: Structural, functional, and therapeutic design perspectives

Gomari, M. M., Ntwali, P. V. M., Choupani, E., & Ashayeri, N. (2026) · New Biotechnology · doi:10.1016/j.nbt.2026.02.010 · Cited by 2 · see citing works

Open-source electrophilic fragment screening platform to identify chemical starting points for UCHL1 covalent inhibitors

Ficarro, S. B., Marto, Z. H., Girardi, N. M., Deng, D., Maisonet, I. J., Adelmant, G., Fleming, L. E., Sharafi, M., Tavares, I., Zhao, A., et al. (2024) · SLAS DISCOVERY · doi:10.1016/j.slasd.2024.100198 · Cited by 1 · see citing works

Overexpression of Protein Kinase C iota as a prognostic marker and its role in oxaliplatin resistance in colorectal cancer

Liao, X., Liu, M., Hong, C., Liu, Y., Li, Q., Chen, Y., Zhang, T., Chen, H., & Fu, S. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04153-x

Characterisation of an allosteric site in PLCγ enzymes and implications for development of their specific inhibitors

Bunney, T. D., Nyvall, H. G., Macrae, C., Lalović, D., Gregory, A., Huray, K. I. P. L., Harvey, N., Pinotsis, N., Kalli, A. C., Waudby, C. A., et al. (2025) · Biochemical Journal · doi:10.1042/bcj20253358

The Cysteinome of Protein Kinases as a Target in Drug Development

Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201707875 · Cited by 237 · see citing works

Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome

Rao, S., Gurbani, D., Du, G., Everley, R. A., Browne, C. M., Chaikuad, A., Tan, L., Schröder, M., Gondi, S. R., Ficarro, S. B., et al. (2019) · Cell chemical biology · doi:10.1016/j.chembiol.2019.02.021 · Cited by 67 · see citing works

Assessment of protein kinases as therapeutic targets (application to the rational design of allosteric covalent inhibitors)

Leproult, É., Wurtz, J., & Moras, D. (2011) · OpenGrey (Institut de l'Information Scientifique et Technique)

Allosteric Inhibitors Target KRAS in a Mutant-Specific Manner

(2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-rw2013-260

Research progress on covalent inhibitors targeting alkaline amino acids

Zhao, B., Xu, S., Zhou, S., Jiang, X., Jiang, A., Lei, H., & Zhai, X. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108800 · Cited by 8 · see citing works